Clinical Trials Browser

Phase 2 × Lymphoma, B-Cell, Marginal Zone × tafasitamab × Clear all

NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

Phase 2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone

NCT06792825 2025-08-12

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Phase 2 Recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone